Blog

This week, we plan on releasing some updates to the reviews and comments functionality. Previously, the two functions were on separate tabs, and we have tried to streamline the interface by unifying overlapping functionality.

This week, we plan on releasing some updates to the reviews and comments functionality. Previously, the two functions were on separate tabs, and we have tried to streamline the interface by unifying overlapping functionality.

After we released the comment functionality last fall, we noticed that many people left comments were more appropriate as reviews. We hope that the new interface will encourage people to leave comments as comments and reviews as reviews.

We're excited for this year, and hope to bring out new features to this site.

We're excited for this year, and hope to bring out new features to this site.

Hopefully, 2023 will be even better than 2022. Happy New Year!

We hope you had an excellent year, and have an opportunity to connect with family and friends over the holidays.

We hope you had an excellent year, and have an opportunity to connect with family and friends over the holidays.

Merry Christmas!

With drug prices already so high, policymakers have been looking for ways to save on medications. One plan has been to allow distributors to import drugs from abroad, taking advantage of the difference in drug pricing across countries. Kaiser Health News reported on some recent state efforts to move forward on drug importation.

With drug prices already so high, policymakers have been looking for ways to save on medications. One plan has been to allow distributors to import drugs from abroad, taking advantage of the difference in drug pricing across countries. Kaiser Health News reported on some recent state efforts to move forward on drug importation.

The idea of importing drugs from other countries seems to have bipartisan support. However, some states have applied for approval and are still waiting for permission from the FDA. The reasons for the delay might not be entirely clear, but it seems likely that the current administration is concerned about the political backlash from pharmaceutical companies that might ensue if the applications were approved. At the same time, delaying meaningful steps to curb the rise of drug prices might engender its own political backlash from ordinary voters.

Colorado launched Colorado Option: an insurance plan administered by private insurance companies, but with the state mandating certain benefits and an overall reduction in premiums over time. Kaiser Health News reported on the plan's rollout. State officials seem intent on gaining better value by insisting on both richer benefits and price reductions. The option apparently requires "unlimited free visits for primary care, mental health care, substance use, and perinatal services, as well as coverage of diabetes supplies like glucose monitors and syringes at no cost," which seems more generous than most insurance plans. Starting with the second year, plans that do not achieve premium reduction targets are subject to review by the Division of Insurance.

Colorado launched Colorado Option: an insurance plan administered by private insurance companies, but with the state mandating certain benefits and an overall reduction in premiums over time. Kaiser Health News reported on the plan's rollout. State officials seem intent on gaining better value by insisting on both richer benefits and price reductions. The option apparently requires "unlimited free visits for primary care, mental health care, substance use, and perinatal services, as well as coverage of diabetes supplies like glucose monitors and syringes at no cost," which seems more generous than most insurance plans. Starting with the second year, plans that do not achieve premium reduction targets are subject to review by the Division of Insurance.

It is unclear how much pressure the review will exert. A state representative that sponsored the legislation seems to believe that insurance companies will try hard to avoid the rate review, but what is not apparent is how much more information those reviews will reveal than is currently available to state regulators. Regardless, it is good to see state governments trying to find new solutions to rising health costs.